Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2018-08-20 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2018年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司 2018 年半年度财务报告" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2018 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2018. The report explicitly states it is a half-year (semi-annual) financial report and includes comprehensive financial data and analysis, not just an announcement or summary. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-20 Chinese
关于向雅伦生物科技（北京）有限公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's capital increase investment in a subsidiary, 雅伦生物科技（北京）有限公司. It details the investment amount, board approvals, shareholding changes, and the purpose and risks of the investment. The document is a formal public announcement of a financing activity, specifically an increase in capital investment in a subsidiary, rather than a full financial report or earnings release. There are no financial statements or detailed financial analysis included, only summary financial data of the investee company. The document fits the category of Capital/Financing Update (CAP) as it reports on the company's financing activity and capital structure changes related to the investment.
2018-08-20 Chinese
2018年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司 2018 年半年度报告全文," which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2018 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion and analysis, financial statements, and other comprehensive information typical of an interim or quarterly report. The document covers the first half of 2018, includes actual financial figures, business performance analysis, and detailed notes on assets, liabilities, and investments. It is not a brief announcement or a presentation but a full report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-20 Chinese
关于控股股东股权解除质押及质押的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the release and new pledging of shares held by the controlling shareholder. It details the number of shares released from pledge, newly pledged shares, pledge dates, pledgees, and the proportion of shares involved. The document includes tables with specific shareholding and pledge data, and it explicitly states that the announcement is about share pledge and release activities. There is no indication of financial statements, earnings data, or management discussion. The document is relatively short (2016 characters) and focuses solely on share pledge status updates. This fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement about share pledge status and does not fit into more specific categories like Share Issue/Capital Change or Transaction in Own Shares, since it concerns pledging of shares by a controlling shareholder rather than issuance or buyback. Therefore, the best classification is Regulatory Filings (RNS).
2018-08-14 Chinese
关于控股股东股权质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the company's controlling shareholder. It details the number of shares pledged, pledge dates, pledgees, and the proportion of shares pledged relative to total holdings. It also assures that the pledge does not affect control of the company and includes references to related documents such as pledge registration certificates. The document is short (1470 characters) and is an announcement of a specific shareholder transaction (share pledge). It does not contain financial statements, audit information, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities including share pledges.
2018-08-06 Chinese
关于获得替格瑞洛片药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration approval from the national drug regulatory authority. It contains no financial statements, no management discussion of financial results, no earnings data, and no mention of shareholder votes or meetings. The document is an official announcement of a regulatory approval related to the company's pharmaceutical product, which is a typical regulatory filing to inform investors and the public about significant company developments. The document length is short (1143 characters), and it is not a report or presentation but an announcement. Therefore, it fits best under Regulatory Filings (RNS).
2018-08-02 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.